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To examine human gene expression during uncomplicated P. falciparum malaria, we obtained three samples (acute illness,
treatment, and recovery) from 10 subjects and utilized each subject’s recovery sample as their baseline. At the time of acute illness
(day 1), subjects had upregulation of innate immune response, cytokine, and inflammation-related genes (IL-1𝛽, IL-6, TNF, and
IFN-𝛾), which was more frequent with parasitemias >100,000 per 𝜇L and body temperatures ≥39∘C. Apoptosis-related genes
(Fas, BAX, and TP53) were upregulated acutely and for several days thereafter (days 1–3). In contrast, the expression of immune-
modulatory (transcription factor 7, HLV-DOA, and CD6) and apoptosis inhibitory (c-myc, caspase 8, and Fas Ligand G) genes was
downregulated initially and returned to normal with clinical recovery (days 7–10). These results indicate that the innate immune
response, cytokine, and apoptosis pathways are upregulated acutely in uncomplicated malaria with concomitant downregulation
of immune-modulatory and apoptosis inhibitory genes.
1. Introduction
Malaria is caused by intracellular protozoa of the genus
Plasmodium [1]. Each year 300 million to 3 billion people are
infected and more than 600,000 die, making malaria the
most important vector-borne disease in the world [2]. Of the
five parasites that infect humans (P. falciparum, P. vivax, P.
malariae, P. ovale, and P. knowlesi), P. falciparum causes the
most severe disease and themostmorbidity andmortality [3].
Its manifestations range from asymptomatic to fatal infection
[4, 5] and there are major gaps in our understanding of its
pathogenesis [6] and the changes in gene expression responsi-
ble for the host response that are the focus of this study [7, 8].
Previous studies have shown that humans with malaria
release proinflammatory mediators, such as tumor necrosis
factor (TNF), interferon gamma (IFN-𝛾), and nitric oxide
(NO), which may damage organs such as brain, lung, and
kidney [5], and suggest that the levels of these mediators are
related to the severity of disease [9–13]. Potential parasite
virulence factors include the glycolipids that anchor parasite
proteins to the red cell surface [14, 15], var genes [16, 17],
and hybrid sequences in parasite proteins on the surface of
parasitized red blood cells (Block 2 region of merozoite
surface protein 1 [OA Koita: personal communication]).
However, until now, it has been difficult to study host
gene expression in malaria because methods available could
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Figure 1: Study design and flow chart for sample collection. The time line (upper left) provides the times when the 3 samples were collected.
The insets provide sample results of the procedures used to test RNA quality: agarose gel electrophoresis performed on-site in Mali (left) and
capillary electrophoresis using the Agilent Biolanalyzer 2100 in New Orleans (right). Flow chart for sample collection, quality control, and
studies performed.
examine only a few genes at a time (Northern blots, reverse
transcriptase PCR). In contrast, cDNA [18] and oligonu-
cleotidemicroarrays [19, 20] permit examination of the entire
human transcriptome. To examine host gene expression in
malaria, it was necessary to examine and resolve (1) effects of
ambient temperatures > 45∘C on RNA stability, (2) transport
of RNA preparations from malarious areas to the U.S., (3)
potential confounding by host genomic differences and host
variation in gene expression, (4) the effects of antimalarial
treatment on host gene expression, and (5) potential false-
positive and false-negative microarray results.
2. Methods
2.1. Blood Collection and RNA Isolation. Venous blood sam-
ples (3mL) were drawn from children 3–16 years of age with
uncomplicated malaria and transferred to tubes containing
Ficoll-Hypaque (CPTTube 362760, BectonDickinson). After
centrifugation at 1,500×g for 20min at room temperature,
peripheral blood mononuclear cells (PBMCs) formed a 1-
2mm layer 5mm above the gel separator which was aspirated
manually (Samco Pipet 335, San Fernando, CA), mixed with
1.3mL RNAlater (Ambion, Austin, TX), and stored at 0∘C
(ice-water bath). Within 2 hours, RNA was isolated from this
suspension using the RiboPure-Blood kit (Ambion).
2.2. RNA Quality. Was assessed by agarose gel (Figure 1) and
OD 260/280 ratios in Mali. Samples with distinct 18S and 28S
bands on agarose gel and OD 260/280 ratios ≥ 1.7 were stored
in sodium acetate : ethanol (0.1 vol 3M sodium acetate, [pH
5.2] : 2.5 vol 98% ethanol) at −20∘C until transport to New
Orleans where they were stored at −20∘C for ≤ 4 weeks. RNA
was purified by ethanol precipitation, followed by cleanup
with the RNeasy Kit (Qiagen). RNA was then reexamined
using the RNA 6000 Nano Marker Green kit (25–6,000 nt
standards, Ambion) and the 2100 Bioanalyzer (Agilent Tech-
nologies, Waldbronn, GERMANY) to identify 18S and 28S
ribosomal peaks on the electropherogram and estimate the
RNA IntegrityNumber (RIN) [21]. Samples withwell-defined
18S and 28S peaks on the electropherogram, ≥1.0 𝜇g RNA,
and RINs ≥ 6.5 were converted to biotinylated cRNA and
hybridized (Figure 1).
2.3. Conversion of mRNA to Double-Stranded Biotinylated
cRNA. Double-stranded cDNA was synthesized using the
Superscript system (Invitrogen), purified by phenol : chloroform
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extraction, and concentrated by ethanol precipitation. In
vitro transcription was used to produce biotin-labeled cRNA
(GeneChip In Vitro Transcription Labeling Kit, Affymetrix).
2.4. Microarray Hybridization. Biotinylated cRNA was
cleaned (RNeasy), fragmented, and hybridized on HG-U133
Plus 2.0 chips (Affymetrix). Each chip had> 54,000 probe sets
for > 38,000 human genes [22]. After washing, chips were
stained with streptavidin-phycoerythrin, amplified with
biotinylated anti-streptavidin (Vector Laboratories), and
scanned for fluorescence (GeneChip Scanner 3000) using
the GeneChip Operating software, version 1.0 (GCOS).
2.5. Microarray Data Processing. Fluorescence intensities for
perfect match (PM) and mismatch (MM) nucleotides were
used to determine whether mRNA for specific genes was
present (P), marginally present (M) or absent (A). Scanned
images were transferred to dChip [23–25] and corrected for
image discontinuities. To compare results across chips, one
array was chosen as baseline (147C, median intensity 167) to
which others were normalized by calculating expression val-
ues based on PMs and MMs. Negative results were assigned
a value of one.
2.6. Filtering. Was performed to identify genes with changes
in expression between (1) acute illness (A) and recovery (C),
(2) acute illness (A) and treatment (B), or (3) treatment (B)
and recovery (C) based on ≥ 90% confidence in a ≥ 1.5-
fold change in fluorescence (p < 0.01) and a P-call ≥ 70% for
samples with up- or downregulation. Samples were permuted
100 times to estimate the false discovery rate which was 0.0%
(median), 90% CI: 16.4–25.2%. The three sets of genes were
then combined by removing duplicate genes and genes with
redundant probe sets.
2.7. Hierarchical Clustering in dChip. Expression values were
standardized by adjusting samples linearly to a mean of
zero with a standard deviation of one and by determining
correlation coefficients (𝑟 values) for normalized expression
(intergenic distances defined as 1−𝑟). Genes with the shortest
distances between them were merged into supergenes, con-
nected in dendrograms using lengths proportional to genetic
distance (centroid-linkage), and repeated 𝑛−1 times to cluster
all genes. A similar algorithm was used to cluster the samples
[26, 27].
2.8. Gene Ontologies. Five patterns of expression on the
heat maps were examined for Gene Ontology (GO) term
enrichment [28] across the entire microarray by using the
exact hypergeometric distribution (significant 𝑝 values <
0.01).
2.9. Filtering Based on Parasitemia and Temperature (Table 1).
Was based on acute illness samples and used analysis of
variance (𝑝 values ≤ 0.01 and P-calls ≥ 20%); hierarchical
clustering was used to identify patterns of expression and to
test for GO term enrichment.
Table 1: Baseline information at the time of enrollment: subjects
with uncomplicated P. falciparummalaria and uninfected controls.
Subjects
Age
(years)
Sex
(M, F)
Temperature
(∘C)
Parasitemia
(per 𝜇L)
6 F 37.9 1,400
13 M 38.0 35,575
14 F 38.0 6,100
9 F 38.6 10,625
7 M 39.4 61,125
16 M 39.6 14,675
14 M 39.6 53,350
3 M 39.7 113,000
9 F 40.0 166,500
11 M 40.0 29,525
Uninfected controls
6 M 36.2 0 (Neg)
4 M 37.2 0 (Neg)
7 F 36.7 0 (Neg
7 F 36.8 0 (Neg)
2 M 36.0 0 (Neg)
2.10. Pathway Analysis and Filtering. Identified genes with
differences in expression between acute illness and recovery
based on (1) ≥ 90% confidence in ≥ 2-fold changes in
expression (up or down) and (2) P-calls of 100% for the
samples in which genes were up- or downregulated.
2.11. Samples from Uninfected Controls. Included 4 subjects
who received chloroquine and one who received placebo
(5% dextrose in saline). After normalization based on sample
2405A (median intensity 153), cRNA from these subjects was
analyzed similarly using dChip.
2.12. Microarray Target Validation. Was performedwith Taq-
Man lowdensity arrays using cDNAprepared from total RNA
(iScript kit, Bio-Rad), loaded in low density cards, and run
on an ABI 7900 HT real-time thermocycler using 50–100 ng
cDNA per well. Data were normalized using endogenous 18S
cDNA as the control to calculate fold changes between sam-
ples with 95%CIs for genes with valid threshold cycle data for
3 or more of 4 replicates (based on acute illness or recovery
samples). Genes with changes in expression that overlapped
the baseline sample (based on the 95% CI) were excluded
from the subsequent analyses.
2.13. Subject Identification, Informed Consent, and Study
Design. Identification of infected subjects was performed at
the Banconi Clinic in Bamako using Giemsa-stained thick
blood smears, a positive parasite antigen test, and PCR for
the polymorphic Block 2 region of msp1 [29]. Informed
consent was obtained before enrollment from the parents or
guardians of children with uncomplicated P. falciparum
malaria using a protocol approved by the Mali IRB in
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Bamako and the Tulane IRB in New Orleans. To control for
host genomic variation and variation in gene expression,
three samples were obtained from each subject (Figure 1):
(1) an acute sample at the time of diagnosis on day 1 before
beginning treatment (A), (2) a treatment sample on day 3 or
4 after completion of the 3-day course of treatment (B), and
(3) a recovery sample 7–10 days after treatment (C, no signs
or symptoms of malaria, no asexual parasites on the thick
smear). The recovery sample served as the baseline to which
the other samples were compared to identify changes from
baseline (normal) gene expression. Relevant clinical data,
including parasitemia and temperature (Table 1), were
obtained at the time of diagnosis and during follow-up visits.
To control for the effects of antimalarials on gene expres-
sion, uninfected healthy controls were identified in the village
of Missira in the Kolokani District (160 km NW of Bamako)
based on a negative Giemsa-stained thick smear, negative
parasite antigen test, and the absence of symptoms or signs of
malaria. After obtaining consent, these subjects were enrolled
in the study and randomized to receive either chloroquine or
placebo (5% dextrose in saline).
3. Results
3.1. Examination of Gene Expression Profiles. Identified three
sets of genes with ≥1.5-fold changes between (1) acute illness
and treatment (𝑛 = 127), (2) acute illness and recovery (𝑛 =
67), or (3) treatment and recovery (𝑛 = 57). These three sets
of genes (Σ = 251) contained 219 unique genes, which were
reduced to 182 by removing redundant probes. Conversely,
when these criteria were used with samples from uninfected
controls, only one gene was identified, indicating that anti-
malarial treatment produced no identifiable changes in gene
expression. Gene expression patterns in the treatment and
recovery groups (B andC) clustered closest to each other, with
the acute illness group (A) beingmost distant.However, those
patterns were not observed with the uninfected controls.
Hierarchical clustering indicated that the uninfected controls
were most similar to the recovery samples (C) and thus the
recovery samples provided an accurate profile of gene expres-
sion in healthy subjects.
Hierarchical clustering of these 182 genes identified five
expression profiles, four of which were linked to Gene Ontol-
ogy (GO) categories such as host immune response or apop-
tosis (Figure 2). These four profiles included (1) genes upreg-
ulated during acute illness (A), (2) genes upregulated during
both acute illness and treatment (AB), (3) genes upregulated
during both treatment and recovery (BC) and (4) genes
upregulated only at the time of recovery (C). The fifth profile
(B), which contained genes upregulated only during treat-
ment, was not included in the subsequent analyses because
those genes were scattered across Gene Ontology categories.
Expression profile A (79 upregulated genes, 65 in 41 GO
categories) included genes involved in the innate immune
response, effector cell activation, and chemotaxis: leukocyte
immunoglobulin-like receptor (LIR) family, neutrophil/
monocyte/macrophage chemotactic chemokine receptor-
like 2 (CCRL2), toll-like receptor 5 (TLR-5), aquaporin 9,
complement component receptor C3AR1, acute-phase
cytokine IL-6, and the IL-1𝛽 receptor antagonist.
Expression profile AB (44 upregulated genes, 41 in 25 GO
categories) included genes involved in the immune response,
apoptosis, and cell death. Immune response genes included
complement components C1qA, C1qB, C1qG, and C2,
chemokine ligand CXCL16, and Fc III 𝛾-receptors CD16a and
CD16b. Upregulated apoptosis- and cell death-related genes
included BCL2-related X-protein (BAX), BH3 interacting
domain death agonist (BID), baculoviral IAP repeat-
containing 5 (survivin), and caspase 5.
Expression profile BC (7 upregulated genes, 7 in 13 GO
categories) included genesinvolved in cellular development
and the response to injury such as myosin regulatory protein
MYL9, bone morphogenic protein 6, thrombospondin 1, and
the oxytocin receptor.
Expression profile C (31 upregulated genes, 27 in 7 GO
categories) includedgenes upregulated at recovery (10–14 days
after acute illness) such as human leukocyte antigens HLA-
DOA and HLA-DOB, transcription factor 7, CD6, CD1C
antigen, and the Fc IgE receptor, FCER1A.
3.2. Pathways (Gene Networks) Involved in Uncomplicated P.
falciparumMalaria. Based on pathway analyses, a number of
cytokine and inflammatory response genes were upregulated,
including IL-6, IL-10, IL-1𝛽, and TNF (Figure 3). Exami-
nation of the apoptosis pathway (Figure 4) demonstrated
simultaneous upregulation of genes that facilitate apoptosis
(BAX,NF-𝜅1B, TNF SF10,GzmB, andTNF) and concomitant
downregulation of genes that inhibit apoptosis (c-Myc, TNF
R SF25, IRF4, KBBKG, caspase 8, and Fas Ligand G).
3.3. Pathway Analyses Based on Parasitemia and Temperature.
Identified 55 genes based on parasitemia and 21 based on
temperature. GenMAPP analyses revealed differences in the
inflammatory and apoptosis pathways between subjects with
low parasitemias and subjects with medium or high para-
sitemias. Within the inflammatory, immune response, and
host response pathways, the differencesweremost striking for
acute phase mediators such as IFN-𝛾, IL-1𝛼, IL-1𝛽, IL-6, IL-7,
IL-10, IL-15, and TNF (Figures 3(a)-3(b)). Within the apop-
tosis pathway, the differences were most striking for TP53
(p53), Fas, Fas Ligand, MCL1, caspases 6, 8, and 10, TNF, and
TNFSF10B and 25 (Figures 4(a)-4(b)). Similar results were
obtainedwith increasing body temperature (data not shown).
3.4. Upregulation of the Inflammatory and Apoptosis Pathways
with Higher Parasitemias. Was identified with ANOVAusing
Kruskal-Wallis. Similar upregulation was observed in sub-
jects with elevated temperatures (< 39∘C versus ≥39∘C, data
not shown).
3.5. Microarray Validation Using Low Density Arrays. Quan-
titative real-time PCR using TaqMan low density arrays
demonstrated excellent correlations between the changes
observed in themicroarrays and low density arrays.Themag-
nitudes of changes (fold increase or decrease) in gene expres-
sion in the inflammatory response and apoptosis pathways
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Figure 2: Heat map for changes in gene expression among subjects with uncomplicated malaria. Changes in gene expression with
uncomplicated P. falciparum malaria revealed five major expression patterns: [A] genes upregulated at the time of acute illness, [AB] genes
upregulated at the times of acute illness and treatment, [B] genes upregulated at the time of treatment, [BC] genes upregulated at the times of
treatment and recovery, and [C] genes upregulated at the time of recovery. Based on Gene Ontology (GO) categories, profile A and AB genes
were related to the immune response, AB genes to apoptosis, and C genes to immune-modulatory functions. In contrast, similar changes in
gene expression were not observed in healthy control subjects without P. falciparummalaria (data not shown). Heat map for changes in gene
expression among subjects with uncomplicated Plasmodium falciparummalaria.
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Figure 3: Inflammatory and cytokine response pathways. GenMAPP illustration of genes upregulated with low parasitemias (a) andmedium
to high parasitemias (b). Several genes were upregulated more frequently with medium or high parasitemias (b) than low parasitemias (a).
Among these were IL-1𝛽, IL-6, IL-10, TNF, and INF-𝛾. Additionally, a number of genes, including IL-7, IL-15, and PGDFA (platelet-derived
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downregulated more with medium to high than low parasitemias.
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Figure 4: Apoptosis response pathway. Expression of most apoptosis-related genes correlated with the parasitemia. Note that the majority of
these genes, including Fas (first apoptosis signal), FasL (Fas Ligand), and TP53 (tumor protein 53), were upregulated in subjects with medium
to high parasitemias. In contrast, the BCL2 interacting protein (BNIP) family gene and the BCL2 and BCL2L1 apoptosis inhibitory genes were
upregulated in subjects with low parasitemias and downregulated in subjects with medium to high parasitemias.
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varied similarly with parasitemia in both the microarrays
(Figures 3-4) and the low density arrays (data not shown).
4. Discussion
4.1. Study Design, Obstacles, and Potential Confounders. The
effects of ambient temperatures > 45∘C in Mali on RNA
quality were addressed by rapid sample processing, by storage
of PBMC preparations at 0∘C in RNAlater until the time
of RNA extraction, and by the evaluation of RNA quality
on-site in Bamako and again in New Orleans. Confounding
by individual variation in gene expression was addressed by
using the recovery samples from each subject as their control.
This study design also permitted the study of changes in
expression over time in pathways that were initially up- or
downregulated. Confounding by antimalarial treatment was
addressed by demonstrating that antimalarial treatment
alone had no effect on gene expression.
4.2. Comparison with Previous Reports. These results provide
the first information of which we are aware for upregulation
of the apoptosis pathway with concomitant downregulation
of apoptosis inhibitory genes during acutemalaria (Figure 4).
In contrast, the upregulation of inflammatory, host response,
and proinflammatory cytokine genes observed (TNF, IFN-𝛾)
is consistentwith previous reports (Figure 3) [5, 7, 9, 10, 15, 23,
24] and there was no upregulation of immune response genes
in the uninfected controls (data not shown). Although some
immune-related genes were downregulated, those downreg-
ulated genes had immune-modulatory functions (Figure 2,
profile BC).
4.3. Pathway Analyses. Revealed upregulation of cytokine,
immune response, inflammatory response, complement acti-
vation (Figure 3), apoptosis (Figure 4), and Fas pathways [30–
32] in subjects with higher parasitemias (25,000–100,000 per
𝜇L and >100,000 per 𝜇L, Figures 3-4) and higher tempera-
tures (≥39∘C, data not shown).
4.4. The Role of the Innate Immune System in Uncompli-
cated P. falciparum Malaria [33–35]. Is supported by the
upregulation of Toll-like receptors (TLR 5) [36, 37], NK cell
receptors (LILRs, KIRs), and chemokines during the acute
illness (day 1). Indeed, several studies have suggested that the
glycosylphosphatidylinositol (GPI) lipopolysaccharidewhich
anchorsP. falciparum proteins to parasite and red cell surfaces
may stimulate the production of proinflammatory cytokines
such as TNF, and Zhu et al. [15] have shown that GPI induc-
tion of IL-6, IL-12, and TNF is dependent on TLR activation
via the p38- and NF-𝜅B pathways. In these studies, IL-1𝛽, IL-
6, andTNFwere upregulatedmore frequently in subjectswith
higher parasitemias (Figures 3-4) and higher temperatures
(data not shown). In addition, studies in Uganda suggest that
individuals heterozygous for the TLR 2 Δ22 polymorphism
may be protected from cerebral malaria [38].
4.5. Apoptosis inMalaria. Thedata reported here are likewise
consistent with previous studies suggesting that apoptosis
plays an important role in the pathogenesis of uncomplicated
falciparum malaria [32, 39–41]. Because they indicate that
genes involved in apoptosis, such as Fas, BAX, and TP53,
are upregulated during uncomplicated P. falciparum malaria
in vivo (Figure 4), they suggest that apoptosis may be ini-
tiated through several different pathways in uncomplicated
malaria, including TNF binding to TNFRSF, Fas (which can
be induced by TNF), TNF binding to FasL, and possibly
HMOX in response to oxidative stress. In these studies,
upregulation of apoptosis-related genes correlated with
higher parasitemias (>100,000 per 𝜇L, Figure 4) and higher
body temperatures (≥39∘C, data not shown).These results are
also consistent with the findings of Wassmer et al. [42] who
suggested that TGF-𝛽1 from activated platelets may stimulate
endothelial cell apoptosis and death in cerebral malaria.
Despite the evidence from these and other studies for apopto-
sis in P. falciparum infection, the actual role(s) of apoptosis in
malaria remains unclear although a number of studies have
reported that this pathway is upregulated in severe malaria
[6, 43, 44].
5. Conclusions
The data reported here indicate that the immune response,
proinflammatory, and apoptosis pathways are upregulated
at the time of acute illness in uncomplicated P. falciparum
malaria. The apoptosis pathway remains upregulated for
several days (days 1–3) before returning to normal. In con-
trast, immune-modulatory and apoptosis inhibitory genes
are downregulated initially (days 1–3) and return to normal
by the time of clinical recovery 7–10 days later.
Abbreviations
Abs: Absent
BAX: BCL2 associated X-protein
CI: Confidence interval
GCOS: Gene chip operating system
GO: Gene Ontology
GPI: Glycosylphosphatidylinositol
HG-U133 Plus 2.0: Gene chip for the study of human
gene expression
ID: Identification (as in Gene ID
Number)
Marg: Marginal
MM: Mismatch
msp1: Merozoite surface protein 1
PM: Perfect match
Pres: Present
RIN: RNA integrity number
TNF: Tumor necrosis factor
TP53: Tumor protein 53 (p53).
Disclosure
Thiswork was presented in part at the International Congress
of Immunogenomics in Budapest, Hungary, in October 2006
(Abstract SY12-O-09), and at the 55th annual meeting of the
Journal of Immunology Research 9
American Society of Tropical Medicine in Atlanta, GA, in
November 2006 (Abstract 304).
Conflict of Interests
The authors of this paper state that they have no commercial
or other associations which might pose a conflict of interests.
Authors’ Contribution
James M. Colborn and Joni H. Ylo¨stalo contributed equally
to this work.
Acknowledgments
The authors thank Fawaz Mzayek for his help in planning
and performing the statistical analyses and Barbara Beck-
man, Frank B. Cogswell, Kaushal Deepak, Elizabeth Didier,
Marcelo Kuroda, Michelle Lacey, Frances J. Mather, Tunika
I. Okatcha, Sudesh Srivastav, and Young Hong for their
thoughtful reviews of the paper. These studies were sup-
ported by the Emerging Infectious Diseases Program of the
Centers for Disease Control and Prevention (Cooperative
Agreements CCU/UR3 418652 and U01 CI 000211) and by a
Tulane University Research Enhancement Award to DJK.
References
[1] P. C. C. Garnham,Malaria Parasites and Other Haemosporidia,
Blackwell Scientific, Oxford, UK, 1966.
[2] Global Health Observatory, “Malaria,” 2015, http://www.who
.int/gho/malaria/.
[3] Centers for Disease Control and Prevention, “Malaria,” January
2015, http://www.cdc.gov/malaria/.
[4] B. Greenwood, K. Marsh, and R. Snow, “Why do some African
children develop severe malaria?” Parasitology Today, vol. 7, no.
10, pp. 277–281, 1991.
[5] L. H. Miller, D. I. Baruch, K. Marsh, and O. K. Doumbo, “The
pathogenic basis of malaria,”Nature, vol. 415, no. 6872, pp. 673–
679, 2002.
[6] N.H.Hunt, J. Golenser, T. Chan-Ling et al., “Immunopathogen-
esis of cerebral malaria,” International Journal for Parasitology,
vol. 36, no. 5, pp. 569–582, 2006.
[7] L. Schofield and G. E. Grau, “Immunological processes in
malaria pathogenesis,” Nature Reviews Immunology, vol. 5, no.
9, pp. 722–735, 2005.
[8] M. J. Griffiths, M. J. Shafi, S. J. Popper et al., “Genomewide
analysis of the host response to malaria in Kenyan children,”
Journal of InfectiousDiseases, vol. 191, no. 10, pp. 1599–1611, 2005.
[9] B. G. Mordmu¨ller, W. G. Metzger, P. Juillard et al., “Tumor
necrosis factor in Plasmodium falciparummalaria: high plasma
level is associated with fever, but high production capacity is
associated with rapid fever clearance,” European Cytokine Net-
work, vol. 8, no. 1, pp. 29–35, 1997.
[10] P. H. Jakobsen, R. Moon, R. G. Ridley et al., “Tumour necrosis
factor and interleukin-6 production induced by components
associated with merozoite proteins of Plasmodium falciparum,”
Parasite Immunology, vol. 15, no. 4, pp. 229–237, 1993.
[11] D. Kwiatkowski, J. G. Cannon, K. R. Manogue, A. Cerami, C.
A. Dinarello, and B. M. Greenwood, “Tumour necrosis factor
production in Falciparum malaria and its association with
schizont rupture,” Clinical & Experimental Immunology, vol. 77,
no. 3, pp. 361–366, 1989.
[12] C. A. W. Bate, J. Taverne, E. Roman, C. Moreno, and J. H. L.
Playfair, “Tumour necrosis factor induction bymalaria exoanti-
gens depends upon phospholipid,” Immunology, vol. 75, no. 1,
pp. 129–135, 1992.
[13] W. McGuire, A. V. S. Hill, C. E. M. Allsopp, B. M. Greenwood,
and D. Kwiatkowski, “Variation in the TNF-alpha promoter
region associated with susceptibility to cerebral malaria,”
Nature, vol. 371, no. 6497, pp. 508–511, 1994.
[14] L. Schofield, M. C. Hewittt, K. Evans, M. A. Slomos, and P. H.
Seeberger, “Synthetic GPI as a candidate anti-toxic vaccine in a
model of malaria,”Nature, vol. 418, no. 6899, pp. 785–789, 2002.
[15] J. Zhu,G.Krishnegowda, andD.C.Gowda, “Induction of proin-
flammatory responses in macrophages by the glycosylphos-
phatidylinositols of Plasmodium falciparum: the requirement
of extracellular signal-regulated kinase, p38, c-Jun N-terminal
kinase and NF-kappaB pathways for the expression of proin-
flammatory cytokines and nitric oxide,”The Journal of Biological
Chemistry, vol. 280, no. 9, pp. 8617–8627, 2005.
[16] X. Z. Su, V. M. Heatwole, S. P. Wertheimer et al., “The large
diverse gene family var encodes proteins involved in cytoad-
herence and antigenic variation of Plasmodium falciparum-
infected erythrocytes,” Cell, vol. 82, no. 1, pp. 89–100, 1995.
[17] H. M. Kyriacou, G. N. Stone, R. J. Challis et al., “Differential
var gene transcription in Plasmodium falciparum isolates from
patients with cerebral malaria compared to hyperparasitaemia,”
Molecular and Biochemical Parasitology, vol. 150, no. 2, pp. 211–
218, 2006.
[18] M. Schena, D. Shalon, R. W. Davis, and P. O. Brown, “Quantita-
tive monitoring of gene expression patterns with a complemen-
tary DNA microarray,” Science, vol. 270, no. 5235, pp. 467–470,
1995.
[19] R. J. Lipshutz, S. P. A. Fodor, T. R. Gingeras, and D. J. Lockhart,
“High density synthetic oligonucleotide arrays,” Nature Genet-
ics, vol. 21, no. 1, pp. 20–24, 1999.
[20] D. J. Lockhart, H. Dong, M. C. Byrne et al., “Expression moni-
toring by hybridization to high-density oligonucleotide arrays,”
Nature Biotechnology, vol. 14, no. 13, pp. 1675–1680, 1996.
[21] A. Schroeder, O. Mueller, S. Stocker et al., “The RIN: an
RNA integrity number for assigning integrity values to RNA
measurements,” BMCMolecular Biology, vol. 7, article 3, 2006.
[22] R. J. Lipshutz, S. P. A. Fodor, T. R. Gingeras, and D. J. Lockhart,
“High density synthetic oligonucleotide arrays,” Nature Genet-
ics, vol. 21, supplement 1, pp. 20–24, 1999.
[23] C. Li andW.H.Wong, “Model-based analysis of oligonucleotide
arrays: expression index computation and outlier detection,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 98, no. 1, pp. 31–36, 2001.
[24] S. Zhong, C. Li, and W. H. Wong, “ChipInfo: software for
extracting gene annotation and gene ontology information for
microarray analysis,” Nucleic Acids Research, vol. 31, no. 13, pp.
3483–3486, 2003.
[25] C. Li and W. H. Wong, “DNA-chip analyzer (dChip),” in The
Analysis of Gene Expression Data: Methods and Software, G.
Parmigiani, E. S. Garrett, R. A. Irizarry, and S. L. Zeger, Eds.,
pp. 1–446, Springer, New York, NY, USA, 2003.
[26] T. R. Golub, D. K. Slonim, P. Tamayo et al., “Molecular classi-
fication of cancer: class discovery and class prediction by gene
10 Journal of Immunology Research
expression monitoring,” Science, vol. 286, no. 5439, pp. 531–527,
1999.
[27] M. B. Eisen, P. T. Spellman, P. O. Brown, and D. Botstein, “Clus-
ter analysis and display of genome-wide expression patterns,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 95, no. 25, pp. 14863–14868, 1998.
[28] M. Ashburner, C. A. Ball, J. A. Blake et al., “Gene ontology: tool
for the unification of biology,”Nature Genetics, vol. 25, no. 1, pp.
25–29, 2000.
[29] J. M. Colborn, O. A. Koita, O. Cisse´, M. W. Bagayoko, E. J.
Guthrie, and D. J. Krogstad, “Identifying and quantifying geno-
types in polyclonal infections due to single species,” Emerging
Infectious Diseases, vol. 12, no. 3, pp. 475–482, 2006.
[30] K. D. Dahlquist, N. Salomonis, K. Vranizan, S. C. Lawlor, and B.
R. Conklin, “GenMAPP, a new tool for viewing and analyzing
microarray data on biological pathways,” Nature Genetics, vol.
31, no. 1, pp. 19–20, 2002.
[31] S.W. Doniger, N. Salomonis, K. D. Dahlquist, K. Vranizan, S. C.
Lawlor, and B. R. Conklin, “MAPPFinder: using gene ontology
and GenMAPP to create a global gene-expression profile from
microarray data,” Genome Biology, vol. 4, article R7, 2003.
[32] P. Kern, M. Dietrich, C. Hemmer, and N. Wellinghausen,
“Increased levels of soluble Fas ligand in serum in Plasmodium
falciparum malaria,” Infection and Immunity, vol. 68, no. 5, pp.
3061–3063, 2000.
[33] M. Baratin, S. Roetynck, C. Le´polard et al., “Natural killer
cell and macrophage cooperation in MyD88-dependent innate
responses to Plasmodium falciparum,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 102, no. 41, pp. 14747–14752, 2005.
[34] D. S. Hansen, K. J. Evans, M. C. D’Ombrain et al., “The natural
killer complex regulates severe malarial pathogenesis and influ-
ences acquired immune responses to Plasmodium berghei
ANKA,” Infection and Immunity, vol. 73, no. 4, pp. 2288–2297,
2005.
[35] B. Beutler, “Innate immunity: an overview,” Molecular
Immunology, vol. 40, no. 12, pp. 845–859, 2004.
[36] H. Ha¨cker, V. Redecke, B. Blagoev et al., “Specificity in Toll-like
receptor signalling through distinct effector functions of
TRAF3 and TRAF6,” Nature, vol. 439, no. 7073, pp. 204–207,
2006.
[37] B. Beutler, “Inferences, questions and possibilities in Toll-like
receptor signalling,” Nature, vol. 430, no. 6996, pp. 257–263,
2004.
[38] J. A. Greene, N. Sam-Agudu, C. C. John, R. O. Opoka, P. A. Zim-
merman, and J. W. Kazura, “Toll-like receptor polymorphisms
and cerebral malaria: TLR2 Δ22 polymorphism is associated
with protection from cerebral malaria in a case control study,”
Malaria Journal, vol. 11, article 47, 2012.
[39] A. T. Balde´, J. L. Sarthou, andC. Roussilhon, “AcutePlasmodium
falciparum infection is associated with increased percentages of
apoptotic cells,” Immunology Letters, vol. 46, no. 1-2, pp. 59–62,
1995.
[40] A. T. Balde, G. Aribot, A. Tall, A. Spiegel, and C. Roussilhon,
“Apoptosis modulation in mononuclear cells recovered from
individuals exposed to Plasmodium falciparum infection,” Par-
asite Immunology, vol. 22, no. 6, pp. 307–318, 2000.
[41] C. J. Hemmer, H. A. Lehr, K. Westphal, M. Unverricht, M.
Kratzius, and E. C. Reisinger, “Plasmodium falciparummalaria:
reduction of endothelial cell apoptosis in vitro,” Infection and
Immunity, vol. 73, no. 3, pp. 1764–1770, 2005.
[42] S. C. Wassmer, J. B. de Souza, C. Fre`re, F. J. Candal, I. Juhan-
Vague, and G. E. Grau, “TGF-beta1 released from activated
platelets can induce TNF-stimulated human brain endothelium
apoptosis: A new mechanism for microvascular lesion during
cerebral malaria,” Journal of Immunology, vol. 176, no. 2, pp.
1180–1184, 2006.
[43] F. S. Toure´, O. Ouwe-Missi-Oukem-Boyer, U. Bisvigou et al.,
“Apoptosis: a potential triggering mechanism of neurological
manifestation in Plasmodium falciparum malaria,” Parasite
Immunology, vol. 30, no. 1, pp. 47–51, 2008.
[44] C. Punsawad, Y. Maneerat, U. Chaisri, K. Nantavisai, and P.
Viriyavejakul, “Nuclear factor kappa B modulates apoptosis in
the brain endothelial cells and intravascular leukocytes of fatal
cerebral malaria,”Malaria Journal, vol. 12, article 260, 2013.
